Stockscreener 앱 받기
0.5759
6.63%
-0.0409
시간 외 거래:
.59
0.0141
+2.45%
전일 마감가:
$0.6168
열려 있는:
$0.62
하루 거래량:
445.43K
Relative Volume:
0.97
시가총액:
$10.11M
수익:
$10.48M
순이익/손실:
$-37.74M
주가수익비율:
-0.0356
EPS:
-16.1846
순현금흐름:
$-29.03M
1주 성능:
-22.90%
1개월 성능:
-31.44%
6개월 성능:
-48.58%
1년 성능:
-89.15%
1일 변동 폭
$0.55
$0.63
1주일 범위
$0.55
$0.76
52주 변동 폭
$0.55
$21.60
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
JAGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.5759 | 10.11M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
JAGX stock touches 52-week low at $0.56 amid sharp decline By Investing.com - Investing.com South Africa
Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs - ACCESS Newswire
Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi - ACCESS Newswire
Jaguar Animal Health Co-Sponsoring Closing Ceremony at Veterinary Cancer Society Annual Conference on October 15th to Drive Awareness of Jaguar's Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative - ACCESS Newswire
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions - ACCESS Newswire
Jaguar Health, Inc. Reports 2020 First Quarter Financial Results - ACCESS Newswire
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Promotes Carol Lizak to Chief Financial Officer - ACCESS Newswire
Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea - ACCESS Newswire
Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross Proceeds - ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health to Host Investor Call May 15th at 8:30 a.m. Eastern Regarding Q1 2020 Financials & Business Updates - ACCESS Newswire
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs - ACCESS Newswire
Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 - ACCESS Newswire
REMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therap - ACCESS Newswire
UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million - ACCESS Newswire
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs - ACCESS Newswire
Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi) - ACCESS Newswire
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials - ACCESS Newswire
Jaguar Health adopts limited duration stockholder rights plan - TipRanks
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value - Weatherford Democrat
Acquisition Target? Why Jaguar Health Just Activated Its Defensive Measures - StockTitan
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea - ACCESS Newswire
Why Jaguar Health Stock Is Soaring After-Hours - MSN
Jaguar Health Stock Plummets to 52-Week Low of $0.78 By Investing.com - Investing.com Australia
Jaguar Health Stock Plummets to 52-Week Low of $0.78 - Investing.com
Form DEF 14A Jaguar Health, Inc. For: Mar 13 - StreetInsider.com
Jaguar Health extends debt maturity to 2026 By Investing.com - Investing.com Australia
Jaguar Health extends debt maturity to 2026 - Investing.com India
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease StudyShort Bowel Syndrome with Intestinal Failure (SBS-IF) - Yahoo Finance
Rare Disease Breakthrough? Jaguar's Drug Gets Double European Green Light - StockTitan
Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges - MSN
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern - accessnewswire.com
Jaguar Health extends collaboration with Streeterville - TipRanks
Jaguar Health advances cholera treatment, eyes FDA voucher - Investing.com India
Jaguar Health extends collaboration with Streeterville to develop P-300 - TipRanks
Jaguar Health advances cholera treatment, eyes FDA voucher By Investing.com - Investing.com Nigeria
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300 - ACCESS Newswire
Jaguar Health's Cholera Drug Could Unlock $350M FDA Voucher as WHO Declares Emergency - StockTitan
Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website - ACCESS Newswire
Jaguar Health to Host Investor Webcast Monday, November 14th at 8:30 AM Eastern Time Regarding Q3 2022 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - WSIL TV
Exclusive Investor Presentation: Jaguar Health CEO Reveals Strategic Roadmap and Growth Catalysts - StockTitan
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote - ACCESS Newswire
Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020 - ACCESS Newswire
Jaguar Health Provides Updates Regarding Company Capitalization Strategy - ACCESS Newswire
Jaguar Health to Present at Biotech Showcase 2019 in San Francisco - ACCESS Newswire
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference - Huntsville Item
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):